## **Supplementary Online Content**

Saldanha IJ, Lindsley KB, Lum F, Dickersin K, Li T. Reliability of the evidence addressing treatment of corneal diseases: a summary of systematic reviews. *JAMA Ophthalmol*. Published online May 9, 2019. doi:10.1001/jamaophthalmol.2019.1063

**eAppendix.** Diseases, Interventions, Outcomes, and Number of Studies and Participants, and Conclusions of all 65 Reliable Systematic Reviews Addressing Corneal Diseases

This supplementary material has been provided by the authors to give readers additional information about their work.

Author					Number	Number of	
(Year) <sup>Ref</sup>	Condition(s)		T (a) . a f		of	participants	
(TCar)	Condition(s) addressed	Objectives	Type(s) of interventions	Outcomes	included studies	in included studies	Conclusion(s) from the abstract
	audiesseu	"To assess the efficacy of	interventions	Outcomes	studies	studies	conclusion(s) from the abstract
		corneal collagen cross-linking		Symptom resolution;			"Collagen cross-linking seems promising in the
Papaioannou		in the management of		Adverse events; Other			management of infectious keratitis, excluding viral
(2016) <sup>1</sup>	Bacterial keratitis	infectious keratitis"	Surgeries	outcomes	25	209	infections."
, ,		"To assess the effectiveness	J				
		and safety of corticosteroids					"There is inadequate evidence as to the
		as adjunctive therapy for		Visual acuity; Treatment			effectiveness and safety of adjunctive topical
		bacterial keratitis. Secondary		success; Anatomic			corticosteroids compared with no topical
		objectives included evaluation		outcomes; Quality of			corticosteroids in improving visual acuity,
Herretes		of health economic outcomes		life; Costs; Adverse			infiltrate/scar size, or adverse events among
(2014) <sup>2</sup>	Bacterial keratitis	and quality of life outcomes."	Medications	events	4	611	participants with bacterial keratitis."
							"Results of this review suggest no evidence of
		"To evaluate the effectiveness		Treatment success;			difference in comparative effectiveness between
MaDarald		of topical antibiotics in the		Symptom resolution;			fluoroquinolones and aminoglycoside–
McDonald (2014) <sup>3</sup>	Doctorial koratitic	management of bacterial keratitis"	Madications	Adverse events; Other	16	Not	cephalosporin treatment options in the
(2014)	Bacterial keratitis	"To assess and compare data	Medications	outcomes	16	reported	management of bacterial keratitis."
		on the efficacy and safety of					"There is no high-quality evidence of the safety and
		topical treatments (including					efficacy of topical treatments for BKC, which
		antibiotics, steroids,					resulted in uncertainty about the indications and
		immunosuppressants and					effectiveness of topical treatment. Clinical trials are
		lubricants), alone or in					required to test efficacy and safety of current and
		combination, for		Visual acuity; Symptom			any future treatments. Outcome measures need to
		blepharconjunctivitis (BKC) in		improvement; Quality of			be developed which can capture both objective
O'Gallagher	Blepharitis;	children from birth to 16		life; Costs; Adverse			clinical and patient-reported aspects of the
(2017) <sup>4</sup>	conjunctivitis	years"	Medications	events; Other outcomes	1	137	condition and treatments."
		"To assess and compare data					
		on the efficacy and safety of					
		systemic treatments (including					
		antibiotics, nutritional					
		supplements and					
		immunosuppressants), alone		Visual souituu Cumptom			
		or in combination, for blepharconjunctivitis (BKC) in		Visual acuity; Symptom improvement; Costs;			"Conjunctival limbal autograft (CLA) has better
O'Gallagher	Blepharitis;	children aged between zero to		Adverse events; Other			therapy efficacy against the recurrence of
(2016) <sup>5</sup>	conjunctivitis	16 years"	Medications	outcomes	0	0	pterygium than mitomycin C."
(2010)	Conjunctivitio	20 years	.vicalcations	- Catcomes	<u> </u>		"Despite identifying 34 trials related to treatments
							for blepharitis, there is no strong evidence for any
							of the treatments in terms of curing chronic
							blepharitis. Commercial products are marketed to
							consumers and prescribed to patients without
							substantial evidence of effectiveness. Further
							research is needed to evaluate the effectiveness of
		"To examine the effectiveness					such treatments. Any RCT designed for this purpose
		of interventions in the	Medications;	Symptom improvement;			should separate participants by type of condition
Lindsley		treatment of chronic	Other (Lid	Quality of life; Costs;			(e.g. staphylococcal blepharitis or MGD) in order to
(2012) <sup>6</sup>	Blepharitis	blepharitis"	hygiene)	Adverse events	34	2169	minimize imbalances between groups (type I

Author					Number	Number of	
					of	participants	
(Year) <sup>Ref</sup>	Condition(s)		Type(s) of		included	in included	
	addressed	Objectives	interventions	Outcomes	studies	studies	Conclusion(s) from the abstract
							errors) and to achieve statistical power for analyses
							(prevent type II errors). Medical interventions and
							commercial products should be compared with
							conventional lid hygiene measures, such as warm
							compresses and eyelid margin washing, to
							determine effectiveness, as well as head-to-head to
							show comparative effectiveness between
							treatments. Outcomes of interest should be
							patientcentered and measured using validated
							questionnaires or scales. It is important that
							participants be followed long-term, at least one
							year, to assess chronic outcomes properly."
							"There was high quality evidence to support the effectiveness of topical azelaic acid, topical
							ivermectin, brimonidine, doxycycline and
							isotretinoin for rosacea. Moderate quality evidence
							was available for topical metronidazole and oral
							tetracycline. There was low quality evidence for
							low dose minocycline, laser and intense pulsed
							light therapy and ciclosporin ophthalmic emulsion
							for ocular rosacea. Time needed to response and
							response duration should be addressed more
		"To assess the efficacy and					completely, with more rigorous reporting of
van Zuuren		safety of treatments for		Quality of life; Adverse			adverse events. Further studies on treatment of
$(2015)^7$	Blepharitis	rosacea"	Medications	events; Other outcomes	106	13631	ocular rosacea are warranted."
		"To assess the safety and					
		efficacy of topical olopatadine					
		versus placebo and other					
		topical anti-allergic					"Trials included in this review suggest that treating
		medications in treating allergic		Symptom improvement;			simple corneal abrasions with a patch may not
Kam (2017) <sup>8</sup>	Conjunctivitis	conjunctivitis"	Medications	Adverse events	23	3388	improve healing or reduce pain."
		"To assess the effects of					
		topical antihistamines and					"It seems that all reported topical antihistamines
		mast cell stabilisers, alone or					and mast cell stabilisers reduce symptoms and
		in combination, for use in					signs of seasonal allergic conjunctivitis when
		treating seasonal and		Symptom improvement;		l	compared with placebo in the short term.
Castillo	0	perennial allergic	A A a dia a tia	Adverse events; Other	20	Not	However, there is no long-term data on their
(2015) <sup>9</sup>	Conjunctivitis	conjunctivitis"	Medications	outcomes	30	reported	efficacy."
		"To systematically review the					
		effectiveness and safety of					"Generally moderate to strong evidence super-
		subcutaneous immunotherapy (SCIT) for treatment of allergic					"Generally moderate to strong evidence supports the effectiveness of SCIT for treatment of allergic
		rhinoconjunctivitis and		Symptom improvement;			rhinitis and asthma, particularly with single-
		asthma, using formulations		Quality of life; Costs;			allergen immunotherapy regimens. Adverse
Erekosima		currently approved in the		Adverse events; Other			reactions to SCIT are common, but no deaths were
(2014) <sup>10</sup>	Conjunctivitis	United States"	Medications	outcomes	61	3577	reported in the included studies."
(2014)	Conjunctivitis	Officed States	iviculcations	Outcomes	OI	3311	reported in the included studies.

Author					Number	Number of	
					of	participants	
(Year) <sup>Ref</sup>	Condition(s)		Type(s) of		included	in included	
	addressed	Objectives	interventions	Outcomes	studies	studies	Conclusion(s) from the abstract
		"To identify in the most					"Randomized double-blind controlled trials show a
		important databases, up to					favorable risk-benefit ratio in rupatadine for the
		January 2013, the double-					treatment of allergic rhino-conjunctivitis. This
		blind placebo-controlled					evidence is strengthened when data are pooled in
		randomized trials		Symptom improvement;			the form of metaanalysis, where accurate and
Compalati		administering rupatadine in		Adverse events; Other			robust effect estimations are derived from a large
(2013)11	Conjunctivitis	allergic rhinitis"	Medications	outcomes	10	2573	population."
		"To assess the available					
		evidence for an effect of					
		leukotriene receptor					
		antagonists (LTRAs) on the					"In seasonal allergic conjunctivitis, LTRAs are more
Gane	6	ocular symptoms of allergic	NA - dia - dia	6	40	Not	efficacious than placebo but less efficacious than
(2013)12	Conjunctivitis	eye disease"	Medications	Symptom improvement	18	reported	oral antihistamines in adult patients."
		"To assess the efficacy and					
		safety of topical cyclosporine versus placebo in the					"This systematic review and meta-analysis suggests
Wan		treatment of allergic		Symptom improvement;			topical cyclosporine could be an effective and safe
(2013) <sup>13</sup>	Conjunctivitis	conjunctivitis"	Medications	Adverse events	7	153	treatment method for allergic conjunctivitis."
(2013)	Conjunctivitis	Conjunctivitis	Wiedications	Adverse events	· ·	133	"The overall evidence provides a moderate grade
							level of evidence to support the effectiveness of
							sublingual immunotherapy for the treatment of
		"To systematically review the					allergic rhinitis and asthma, but high-quality studies
		effectiveness and safety of					are still needed to answer questions regarding
		aqueous sublingual					optimal dosing strategies. There were limitations in
		immunotherapy for allergic		Symptom improvement;			the standardization of adverse events reporting,
		rhinoconjunctivitis and		Quality of life; Adverse			but no life-threatening adverse events were noted
Lin (2013) <sup>14</sup>	Conjunctivitis	asthma"	Medications	events; Other outcomes	63	1814	in this review."
		"To describe the effectiveness					
		and safety of subcutaneous					
		immunotherapy and					"With some variation across outcomes, the overall
		sublingual immunotherapy					body of evidence consistently provides moderate
		(off-label use of					to high support for the effectiveness and safety of
		subcutaneous-aqueous					both subcutaneous and sublingual immunotherapy
		allergens for sublingual					for the treatment of allergic rhinitis and asthma.
		desensitization) compared					The evidence to support the use of immunotherapy
		with other therapies for					in children is somewhat weaker than the evidence
		treatment of allergic		Treatment success;			supporting its use in adults. The superiority of one
11. (2042)15	6	rhinoconjunctivitis and	NA - dia dia -	Symptom improvement;	112	Not	route of administration over the other is not
Lin (2013) <sup>15</sup>	Conjunctivitis	asthma"	Medications	Adverse events	142	reported	known."
		"To answer the following clinical questions: What are					
		the effects of empirical					
		treatment in adults and					"In this systematic review we present information
		children with suspected					relating to the effectiveness and safety of the
		bacterial conjunctivitis? What					following interventions: ocular decongestants, oral
Epling		are the effects of treatment in		Symptom improvement;		Not	antibiotics, parenteral antibiotics, saline, topical
(2012) <sup>16</sup>	Conjunctivitis	adults and children with	Medications	Adverse events	44	reported	antibiotics, and warm compresses."
(2012)	Conjunctivitis	addits and children with	ivicuications	MUNEISE ENGLIS		reported	antibiotics, and warm compresses.

Author (Year) <sup>Ref</sup>	Condition(s)	Objectives	Type(s) of	Outcomes	Number of included	Number of participants in included	Conclusion/s) from the chetuset
	addressed	Objectives bacteriologically confirmed	interventions	Outcomes	studies	studies	Conclusion(s) from the abstract
		bacterial conjunctivitis? What					
		are the effects of treatment in					
		adults and children with					
		clinically confirmed					
		gonococcal conjunctivitis?"					
Sheikh (2012) <sup>17</sup>	Conjunctivitis	"To assess the benefits and harms of antibiotic therapy in the management of acute bacterial conjunctivitis"	Medications	Symptom resolution; Costs; Adverse events; Other outcomes	11	3673	"Although acute bacterial conjunctivitis is frequently self limiting, the findings from this updated systematic review suggest that the use of antibiotic eye drops is associated with modestly improved rates of clinical and microbiological remission in comparison to the use of placebo. Use of antibiotic eye drops should therefore be considered in order to speed the resolution of symptoms and infection."
		"To provide evidence on the					
CADTH (2016) <sup>18</sup>	Conjunctivitis	efficacy, safety and cost- effectiveness of olopatadine, in comparison with ketotifen, cromolyn, or placebo to assist in the decision making with respect to these agents for the treatment of allergic conjunctivitis"	Medications	Costs; Adverse events; Other outcomes	12	1388	"According to the available data, we suggest that hinge location may have some effect on corneal sensation and dry eye syndrome after LASIK at the early postoperative period. However, there was no significant difference between the groups at 6 months after surgery. Further wellorganized, prospective, randomized studies involving more patients are warranted."
Calderon (2011) <sup>19</sup>	Conjunctivitis	"To evaluate the efficacy of sublingual immunotherapy compared with placebo for reductions in ocular symptoms, topical ocular medication requirements and conjunctival immediate allergen sensitivity"	Medications	Symptom improvement; Other outcomes	42	3399	"Overall, sublingual immunotherapy is moderately effective in reducing total and individual ocular symptom scores in participants with allergic rhinoconjunctivitis and allergic conjunctivitis."
(2011)	Conjunctivitis	and gen sensitivity	Miculcations	Carer outcomes	74	3333	"Acute conjunctivitis seen in primary care can be
Jefferis (2011) <sup>20</sup>	Conjunctivitis	"To determine the benefit of antibiotics for the treatment of acute infective conjunctivitis in primary care and which subgroups benefit most"	Medications	Symptom improvement	3	814	thought of as a self-limiting condition, with most patients getting better regardless of antibiotic therapy. Patients with purulent discharge or a mild severity of red eye may have a small benefit from antibiotics. Prescribing practices need to be updated, taking into account these results."
		"To systematically review					
Roder		randomized controlled trials (RCTs) to evaluate the effect of immunotherapy with inhalant allergens on symptoms and medication use in children and adolescents		Symptom improvement;		Not	"In conclusion, there is at present insufficient evidence that immunotherapy in any administration form has a positive effect on symptoms and/or medication use in children and
(2008)21	Conjunctivitis	with allergic	Medications	Other outcomes	28	reported	adolescents with allergic rhinoconjunctivitis."

Author					Number	Number of	
(Year) <sup>Ref</sup>	Condition(s) addressed	Objectives	Type(s) of interventions	Outcomes	of included studies	participants in included studies	Conclusion(s) from the abstract
	dudiesseu	rhinoconjunctivitis"	interventions	Outcomes	Studies	Studies	conclusion(s) from the abstract
Swamy (2007) <sup>22</sup>	Conjunctivitis	"To assess the effect of topical Non-Steroidal Anti Inflammatory drugs in the treatment of allergic conjunctivitis"	Medications	Symptom improvement; Symptom resolution	8	712	"This meta-analysis confirms that topical NSAID are significantly more effective at relieving the cardinal symptom: conjunctival itching and improving the cardinal sign: conjunctival injection than placebo treatment."
Sopo (2004) <sup>23</sup>	Conjunctivitis	"To evaluate the clinical efficacy of sublingual immunotherapy (SLIT) in respiratory allergy in children"	Medications	Symptom improvement; Other outcomes	8	372	"SLIT can be currently considered to have low to moderate clinical efficacy in children of at least 4 years of age, monosensitised to house dust mites (HDM), and suffering from mild to moderate persistent asthma. This benefit seems to be adjunctive with respect to the environmental preventive measures against HDM."
(200.)	Conjunctions	"To assess the effectiveness	····caications	Other dutesines		372	preventire measures against 112111
Owen (2004) <sup>24</sup>	Conjunctivitis	and relative efficacy of topicaltreatments for the management of seasonal allergic conjunctivitis"	Medications	Treatment success; Symptom improvement	40	Not reported	"Overall, these findings confirm the benefit of topical mast cell stabilisers and antihistamines over placebo for the treatment of allergic conjunctivitis."
Gonzalez- Lopez		"To determine the efficacy and gather evidence on safety from randomised controlled trials (RCTs) of topical CsA in patients with allergic	Medications;	Symptom improvement; Quality of life; Adverse			"This systematic review highlights the relative scarcity of controlled clinical trials assessing the efficacy of topical CsA therapy in AKC and suggests that evidence on the efficacy and safety of topical CsA treatment in patients with CsA remains limited. However, the data suggest that topical CsA may provide clinical and symptomatic relief in AKC and may help to reduce topical steroid use in patients with steroid-dependent or steroid-resistant AKC. No serious adverse events were reported. Reported adverse events in patients treated with topical CsA include intense stinging and eyelid skin maceration. One patient in the placebo group developed a severe allergic response to maize antigens. However, the total number of patients in the trials was too small to assess the safety of this treatment. Additional well-designed and powered RCTs of topical CsA in AKC are needed. Ideal study designs should include adequate randomisation and concealment of allocation; masking of participants, personnel and outcome assessors; adequate follow-up periods and minimisation of attrition bias; and comparison groups with similar clinical and epidemiologic characteristics. Samples should be large enough to provide sufficient statistical power to assess the safety of CsA and to detect clinically relevant treatment effect sizes of
(2012) <sup>25</sup>	Conjunctivitis	keratonjunctivitis (AKC)"	Supplements	events	3	58	the primary outcomes. Analyses should be

Author (Year) <sup>Ref</sup>	Condition(s)		Type(s) of		Number of included	Number of participants in included	
` ,	addressed	Objectives	interventions	Outcomes	studies	studies	Conclusion(s) from the abstract
							appropriate to the study's design and outcome measures. Moreover, standardisation of outcome measures and follow-up periods across studies would be beneficial to maximise study comparability."
Mantelli (2007) <sup>26</sup>	Conjunctivitis; Corneal edema/opacification	"To assess the efficacy of currently available topical drugs for vernal keratoconjunctivitis (VKC) through a meta-analysis of randomised clinical trials (RCTs)"	Medications	Symptom improvement	10	245	"The currently available topical drugs are effective in treating acute phases of VKC. However, there is a lack of evidence to support the recommendation of one specific type of medication for treating this disorder. There is a need for standard criteria to assess diagnosis and therapy based on severity. There is also a need for RCTs assessing long-term effects of single drugs to control the disease and to prevent complications."
Chen (2016) <sup>27</sup>	Corneal ectasia; Corneal edema/opacification	"To evaluate the efficacy and safety of deep anterior lamellar keratoplasty (DALK) compared with penetrating keratoplasty (PK) for patients who had corneal stromal pathologies without endothelial abnormalities"	Surgeries	Visual acuity; Adverse events	5	Not reported	"DALK is an alternative surgical procedure for corneal stromal pathologies without endothelial abnormalities, with lower efficacy but better safety."
Sykakis (2015) <sup>28</sup>	Corneal ectasia; keratoconus	"To assess whether there is evidence that collage cross-linking (CXL) is an effective and safe treatment for halting the progression of keratoconus compared to no treatment"	Surgeries	Visual acuity; Anatomic outcomes; Quality of life; Costs; Adverse events; Other outcomes	3	444	"The evidence for the use of collage cross-linking (CXL) in the management of keratoconus is limited due the lack of properly conducted RCTs."
Fischer (2015) <sup>29</sup>	Corneal ectasia; keratoconus	"To analyse whether corneal implants are more or equally effective and safer than corneal transplantation or no intervention"	Devices; Surgeries	Visual acuity; Quality of life; Adverse events; Other outcomes	5	627	"The current evidence is not sufficient to prove that intrastromal corneal implants are equally or more effective and safe than corneal transplantation or no intervention for treatingf keratoconus or post-LASIK corneal ectasia. However, the comparison before and after the ring implantations of the single-arm studies have shown that the visual acuity has improved and that improvement has been clinically relevant in a large proportion of patients. Furthermore, the implantation of intrastromal corneal rings seems to be relatively safe and adverse events were minor."
Keane (2014) <sup>30</sup>	Corneal ectasia; keratoconus	"To compare visual outcomes after deep anterior lamellar keratoplasty (DALK) and penetrating keratoplasty for keratoconus, and to compare additional outcomes relating	Surgeries	Visual acuity; Visual function; Adverse events	2	111	"We found no evidence to support a difference in outcomes with regards to best-corrected visual acuity (BCVA) at three months post-graft or at any of the other time points analysed."

Author					Number	Number of	
					of	participants	
(Year) <sup>Ref</sup>	Condition(s)		Type(s) of		included	in included	
	addressed	Objectives	interventions	Outcomes	studies	studies	Conclusion(s) from the abstract
		to factors which may					
		contribute to poor visual					
		outcomes (e.g. astigmatism, graft rejection and failure)"					
		grant rejection and failure)					"Information on the durability of the implants'
							treatment effects and their affects on underlying
							disease processes is limited. This information is
							becoming more important as alternative treatment
							strategies, such as collagen cross-linking aimed at
							strengthening the underlying corneal tissue, are
Health		"To determine the role of					emerging and which might prove to be more
Quality		corneal implants in the		Treatment success;			effective or increase the effectiveness of the
Ontario	Corneal ectasia;	management of corneal		Quality of life; Adverse			implants, particularly in advances stages of corneal
(2009) <sup>31</sup>	keratoconus	thinning disease conditions"	Devices	events	10	609	thinning."
							"The rapid growth of endothelial keratoplasty as
							the treatment of choice for FED is based upon the
							belief that visual recovery is more rapid, surgically
							induced astigmatism (regular and irregular) is less
							and rates of transplant rejection are lower with EK. This change in practice also assumes that the rates
							of long term transplant survival are equal for the
							two procedures. The practical differences between
							the surgical procedures mean that visual recovery
							is inherently more rapid following EK, but this
							review found no strong evidence from RCTs of any
							difference in the final visual outcome between EK
							and PKP for people with FED. This review also
							found that higher order aberrations are fewer
							following EK but endothelial cell loss is greater
							following EK. The RCTs that we included employed
							different EK techniques, which may have a bearing
							on these findings. EK procedures have evolved over
							the years and can be performed using different
							techniques, for example deep lamellar endothelial
							keratoplasty, Descemets stripping endothelial keratoplasty (DSEK), Descemets stripping
							automated endothelial keratoplasty (DSAEK),
		"To compare the benefits and					femtosecond laser-assisted endothelial
		complications related to two					keratoplasty and Descemet membrane endothelial
		surgical methods (endothelial					keratoplasty (DMEK).More RCTs are needed to
		keratoplasty (EK) and					compare PKP with commonly performed EK
		penetrating keratoplasty					procedures such as DSEK, DSAEK and DMEK in
		(PKP)) of replacing the					order to determine the answers to two key
		diseased endothelial layer of		Visual acuity; Anatomic			questions, whether there is any difference in the
		the cornea with a healthy		outcomes; Quality of			final visual outcome between these techniques and
Nanavaty	Corneal	layer in people with Fuchs		life; Costs; Adverse			whether there are differences in the rates of graft
$(2014)^{32}$	edema/opacification	endothelial dystrophy (FED)"	Surgeries	events; Other outcomes	3	136	survival in the long term?"

Author					Number	Number of	
(Year) <sup>Ref</sup>					of	participants	
(Year)	Condition(s)		Type(s) of		included	in included	
	addressed	Objectives	interventions	Outcomes	studies	studies	Conclusion(s) from the abstract
		"To determine the					
		effectiveness of topical non-					
Caldor	Corneal abrasions	steroidal anti-inflammatory				Not	"Tonical NCAIDs are offertive analysis for
Calder (2005) <sup>33</sup>	Corneal abrasion;	drugs (NSAIDs) in	Medications	Trootmant sugges	11	Not	"Topical NSAIDs are effective analgesics for
(2005)**	corneal injury	traumaticcorneal abrasions"	iviedications	Treatment success	11	reported	traumatic corneal abrasions."
El		"To determine if eye patching is a useful treatment for		Commente de la commenta del commenta del commenta de la commenta del commenta de la commenta del commenta de la commenta del commenta del commenta del la commenta del comme			"Eyepatching was not found to improve healing
Flynn (1998) <sup>34</sup>	Corneal abrasion	corneal abrasions"	Dovisos	Symptom resolution;	7	550	rates or reduce pain in patients with corneal abrasions."
(1998)	Corneal abrasion		Devices	Other outcomes	<b>'</b>	550	abrasions.
		"To compare the efficacy of					
		two artificial tears, carboxymethylcellulose (CMC)					"The efficacy of CMC appeared to be better than
		and hyaluronate (HA), in the					that of HA in treating dry eye disease, although
Song		treatment of patients with dry					metaanalysis results were not statistically
(2017) <sup>35</sup>	Dry eye	eye disease"	Medications	Other outcomes	5	251	significant."
(2017)	Di y eye	eye disease	Wiedications	Other outcomes	1	231	"Overall there was inconsistency in the possible
							benefits of AS in improving participant-reported
				Tear production; Tear			symptoms and TBUT and lack of effect based on
				film stability; Tear			other objective clinical measures. Well-planned,
				osmolarity; Tear			large, high-quality RCTs are warranted, in different
				fluorescein clearance;			severities of dry eye and using standardized
		"To evaluate the efficacy and		Impression cytology;			questionnaires to measure participant-reported
		safety of autologous serum		Ocular surface staining;			outcomes and objective clinical tests as well as
		(AS) compared to artificial		Symptom improvement;			objective biomarkers to assess the benefit of AS
Pan (2017) <sup>36</sup>	Dry eye	tears for treating dry eye"	Supplements	Corneal topography	4	72	therapy for dry eye."
	7 - 7 -						"OTC artificial tears may be safe and effective
							means for treating dry eye syndrome; the literature
		"To evaluate the effectiveness		Tear production; Tear			indicates that the majority of OTC artificial tears
		and toxicity of over-the-		film stability; Tear			may have similar efficacies. This conclusion could
		counter (OTC) artificial tear		osmolarity; Ocular			be greatly skewed by the inconsistencies in study
		applications in the treatment		surface staining;			designs and inconsistencies in reporting trial
		of dry eye syndrome		Symptom improvement;			results. Additional research is therefore needed
		compared with another class		Visual acuity; Contrast			before we can draw robust conclusions about the
Pucker		of OTC artificial tears, no		sensitivity; Adverse			effectiveness of individual OTC artificial tear
(2016)37	Dry eye	treatment, or placebo"	Supplements	events	43	3497	formulations."
							"Topical diquafosol seems to be a safe therapeutic
							option for the treatment of dry eye. The high
							variability of the selected RCTs compromised the
							strength of evidence and limits the determination
							of efficacy. However, the topical administration of
							diquafosol seems to be beneficial in improving the
							integrity of the epithelial cell layer of the ocular
		"To evaluate the efficacy and		Tear production; Tear			surface and mucin secretion in patients with dry
		safety of topical diquafosol		film stability; Symptom			eyes. This review indicates a need for standardized
		ophthalmic solution for	Medications;	improvement; Adverse			criteria and methods for evaluation to assess the
Wu (2015) <sup>38</sup>	Dry eye	treatment of dry eye"	Supplements	events	8	1516	efficacy of diquafosol in the future clinical trials."
Zhu (2014) <sup>39</sup>	Dry eye	"To clarify the effects of	Supplements	Tear production; Tear	9	716	"This comprehensive meta-analysis supports the

				Number	Number of	
Condition(s)		Type(s) of		_		
	Objectives		Outcomes			Conclusion(s) from the abstract
	polyunsaturated fatty acids (PUFAs) on dry eye syndrome (DES) through meta-analysis of all relevant randomized		film stability; Ocular surface staining; Symptom improvement			use of PUFA supplementation as a potential effective therapy for DES."
Dry eye	"To systematically review data from randomised clinical trials (RCTs) evaluating efficacy and safety of topical cyclosporine A (CsA) treatment for dry eye disease (DED)"	Medications; Supplements	Tear production; Tear film stability; Tear osmolarity; Ocular surface staining; Artificial tear use; Symptom improvement; Adverse events	18	2479	"Although topical CsA appears to be a safe treatment for DED, evidence emerging from RCTs is limited, and this affects the strength of recommendations to healthcare providers and policymakers for optimal management.  Standardised diagnostic criteria to assess the efficacy of topical CsA are recommended to improve the design of future RCTs in DED."
Dry eye	"Outcomes-based review of reported treatment options for patients with dry eye secondary to Sjögren's syndrome (SS)"	Medications; Devices; Supplements	Tear production; Tear film stability; Artificial tear use; Impression cytology; Ocular surface staining; Corneal sensitivity; Symptom improvement; Adverse events; Other outcomes	62	Not reported	"In the current literature on SS-associated dry eye, there is a paucity of rigorous clinical trials to support therapy recommendations. Nonetheless, the recommended treatments include topical lubricants, topical anti-inflammatory therapy, and tear-conserving strategies. The efficacy of oral secretagogues seems greater in the treatment of oral dryness than ocular dryness. Although oral hydroxychloroquine is commonly prescribed to patients with SS to alleviate fatigue and arthralgias, the literature lacks strong evidence for the efficacy of this treatment for dry eye."
Dry eye	"To assess the effectiveness of acupuncture as a treatment option for treating the condition of dry eye"	Other procedures	Tear production; Tear film stability	6	248	"These results provide limited evidence for the effectiveness of acupuncture for treating dry eye. However, the total number of RCTs, the total sample size and the methodological quality were too low to draw firm conclusions."
Dry eye	"To assess the safety and efficacy of punctal plugs for the management of dry eye"	Devices	Tear production; Tear osmolarity; Artificial tear use; Ocular surface staining; Symptom improvement; Adverse events	7	305	"This systematic review shows a relative scarcity of controlled clinical trials assessing the efficacy of punctal occlusion therapy in dry eye. Although the evidence is very limited, the data suggest that silicone plugs can provide symptomatic relief in severe dry eye. Moreover, temporary collagen plugs appear similarly effective to silicone plugs on a short-term basis."
Dry eye	"To summarize evidence on primary Sjögren syndrome drug therapy from randomized controlled trials"	Medications; Supplements	Adverse events	56	Not reported	"In primary Sjögren syndrome, evidence from controlled trials suggests benefits for pilocarpine and cevimeline for sicca features and topical cyclosporine for moderate or severe dry eye. Antitumor necrosis factor agents have not shown clinical efficacy, and larger controlled trials are needed to establish the efficacy of rituximab."  "The trials included in this review were of variable
	Dry eye  Dry eye	polyunsaturated fatty acids (PUFAs) on dry eye syndrome (DES) through meta-analysis of all relevant randomized controlled trials (RCTs)"  "To systematically review data from randomised clinical trials (RCTs) evaluating efficacy and safety of topical cyclosporine A (CsA) treatment for dry eye disease (DED)"  "Outcomes-based review of reported treatment options for patients with dry eye secondary to Sjögren's syndrome (SS)"  "To assess the effectiveness of acupuncture as a treatment option for treating the condition of dry eye"  To assess the safety and efficacy of punctal plugs for the management of dry eye"  "To summarize evidence on primary Sjögren syndrome drug therapy from randomized controlled trials"	polyunsaturated fatty acids (PUFAs) on dry eye syndrome (DES) through meta-analysis of all relevant randomized controlled trials (RCTs)"  "To systematically review data from randomised clinical trials (RCTs) evaluating efficacy and safety of topical cyclosporine A (CsA) treatment for dry eye disease (DED)"  Medications; Supplements  "Outcomes-based review of reported treatment options for patients with dry eye secondary to Sjögren's Supplements  "To assess the effectiveness of acupuncture as a treatment option for treating the condition of dry eye"  Dry eye  To assess the safety and efficacy of punctal plugs for the management of dry eye"  Dry eye  To summarize evidence on primary Sjögren syndrome drug therapy from randomized controlled trials"  Medications; Supplements  Medications; Supplements	polyunsaturated fatty acids (PUFAs) on dry eye syndrome (DES) through meta-analysis of all relevant randomized controlled trials (RCTs)"  "To systematically review data from randomised clinical trials (RCTs) evaluating efficacy and safety of topical cyclosporine A (CsA) treatment for dry eye disease (DED)"  Dry eye  "Outcomes-based review of reported treatment options for patients with dry eye secondary to Sjögren's syndrome (SS)"  Dry eye  "To assess the effectiveness of acupuncture as a treatment option for treating the condition of dry eye"  Dry eye  Medications; Devices; Supplements  Tear production; Tear film stability; Artificial tear use; Impression cytology; Ocular surface staining; Corneal sensitivity; Symptom improvement; Adverse events; Other outcomes  To assess the effectiveness of acupuncture as a treatment option for treating the condition of dry eye"  Dry eye  Dry eye  Dry eye  Dry eye  Dry eye  Dry eye  Medications; Devices  Medications; Devices  Tear production; Tear film stability. Tear osmolarity; Artificial tear use; Ocular surface staining; Symptom improvement; Adverse events.  Tear production; Tear film stability. Tear osmolarity; Artificial tear use; Ocular surface staining; Symptom improvement; Adverse events.  Medications; Supplements  Medications; Symptom improvement; Adverse events  Medications; Symptom improvement; Adverse events  Adverse events  Adverse events	Condition(s) addressed  Objectives  polyunsaturated fatty acids (PUFAs) on dry eye syndrome (DES) through meta-analysis of all relevant randomized controlled trials (RCTs)"  Tear production; Tear film stability; Tear osmolarity; Ocular surface staining; Artificial tear use; Ocular surface staining; Adverse events  Dry eye  Tear production; Tear film stability; Tear osmolarity; Ocular surface staining; Artificial tear use; Symptom improvement; Adverse events  Tear production; Tear film stability; Tear osmolarity; Ocular surface staining; Artificial tear use; Symptom improvement; Adverse events  Tear production; Tear film stability; Artificial tear use; Symptom improvement; Adverse events  Tear production; Tear film stability; Artificial tear use; Impression cytology; Ocular surface staining; Corneal sensitivity; Symptom improvement; Adverse events  Dry eye  Tear production; Tear film stability; Artificial tear use; Impression cytology; Ocular surface staining; Corneal sensitivity; Symptom improvement; Adverse events; Other outcomes  Tear production; Tear film stability Artificial tear use; Ocular surface staining; Symptom improvement; Adverse events; Other outcomes  Tear production; Tear film stability.  Tear production; Tear osmolarity; Artificial tear use; Ocular surface staining; Symptom improvement; Adverse events of the management of dry eye.  Dry eye  Tear production; Tear osmolarity; Artificial tear use; Ocular surface staining; Symptom improvement; Adverse events  Dry eye  Medications; Supplements  Adverse events  Tear production; Tear osmolarity; Artificial tear use; Ocular surface staining; Symptom improvement; Adverse events  Tear production; Tear osmolarity; Artificial tear use; Ocular surface staining; Symptom improvement; Adverse events  Dry eye  Dry eye  To assess the safety and efficacy and efficacy and efficacy of punctal plugs for the management of dry eye.  Dry eye  Medications;	Condition(s) addressed  Objectives  Polyunstured fatty acids (PUFAs) on dry eye syndrome (DES) through meta-analysis of all relevant randomized controlled trials (RCTs) evaluating efficacy and safety of topical cyclosporine A (CsA) treatment for dry eye disease (DED)*  Dry eye  Outcomes-based review of reported treatment options for patients with dry eye syndrome (SS)*  Outcomes-based review of reported treatment options for patients with dry eye syndrome (SS)*  Ory eye  Tear production; Tear film stability; Artificial tear use; Symptom improvement; Adverse events  Tear production; Tear film stability; Artificial tear use; Symptom improvement; Adverse events  Tear production; Tear film stability; Artificial tear use; Impression cyclogy, Ocular surface staining; Symptom improvement; Adverse events  Tear production; Tear film stability; Artificial tear use; Impression cyclogy, Ocular surface staining; Symptom improvement; Adverse events  Tear production; Tear film stability; Artificial tear use; Impression cyclogy, Ocular surface staining; Symptom improvement; Adverse events  Tear production; Tear film stability; Artificial tear use; Other outcomes  To assess the effectiveness of accupuncture as a treatment option for treating the condition of dry eye*  Other  To assess the safety and efficacy of punctal plugs for the management of dry eye*  Dry eye  To summarize evidence on primary Siggren syndrome dry therapy from randomized controlled trials*  Medications; Supplements  Adverse events  Adverse events  Tear production; Tear film stability  Film stability; Ocular surface staining; Symptom improvement; Adverse events  Tear production; Tear osmolarity; Artificial tear use; Ocular surface staining; Symptom improvement; Adverse events  Tear production; Tear osmolarity; Artificial tear use; Ocular surface staining; Symptom improvement; Adverse events  To summarize evidence on primary Siggren syndrome dry the production; Tear osmolarity; Artificial tear use; Ocular surface staining; Symptom improvement; Adverse events

Author					Number	Number of	
(Year) <sup>Ref</sup>	0 1111 (-)		T(1)		of	participants	
(Teal)	Condition(s)	Ohioativaa	Type(s) of	0	included	in included	Complexion (a) from the abotic at
(2015)45	addressed bacterial) keratitis	Objectives different antifungal drugs in	interventions	Outcomes life; Adverse events;	studies	studies	conclusion(s) from the abstract quality and were generally underpowered. There is
(2015)	Dacterial) Keratitis	the management of fungal		Other outcomes			evidence that natamycin is more effective than
		keratitis"		Other outcomes			voriconazole in the treatment of fungal ulcers.
		Relatitis					Future research should evaluate treatment effects
							according to fungus species."
							"Placebo-controlled studies of HSV epithelial
							keratitis are limited to superseded interventions.
							Trifluridine and acyclovir are more effective than
							idoxuridine or vidarabine and similar in therapeutic
							effectiveness. Brivudine and foscarnet do not
							substantially differ in effectiveness from trifluridine
		"To compare the relative					or acyclovir. Ganciclovir is at least as effective as
		effectiveness of antiviral					acyclovir. The addition of interferon to a nucleoside
		agents, interferon, and					antiviral agent and the combination of
		corneal debridement in the		Symptom resolution;			debridement with antiviral treatment need to be
Wilhelmus	Other (non-	treatment of HSV epithelial	Medications;	Adverse events; Other			further assessed to substantiate any possible
(2015) <sup>46</sup>	bacterial) keratitis	keratitis"	Surgeries	outcomes	137	8333	advantage in healing."
		"To evaluate the relative					
		effectiveness and safety of					
		medical therapy for the		Visual acuity; Symptom			"There is insufficient evidence to evaluate the
Alkharashi	Other (non-	treatment of acanthamoeba		resolution; Adverse			relative effectiveness and safety of medical therapy
(2015) <sup>47</sup>	bacterial) keratitis	keratitis"	Medications	events; Other outcomes	1	55	for the treatment of acanthamoeba keratitis."
		"To answer the following					
		clinical questions: What are the effects of treatments in					
		people with epithelial					
		keratitis? What are the effects					
		of treatments in people with					
		stomal keratitis? What are the					"In this systematic review we present information
		effects of interventions to					relating to the effectiveness and safety of the
		prevent recurrence of ocular					following interventions: adding oral aciclovir to
		herpes simplex? What are the					topical corticosteroids plus topical antiviral
		effects of interventions to					treatment; adding topical corticosteroids to topical
		prevent recurrence of ocular					antiviral treatment; antiviral agents (topical);
Barker	Other (non-	herpes simplex in people with		Adverse events; Other		Not	debridement; interferons (topical); and oral
(2008)48	bacterial) keratitis	corneal grafts?"	Surgeries	outcomes	7	reported	aciclovir."
		"To investigate the					"We did not find any evidence for or against the
		effectiveness, and when					effectiveness of non-surgical interventions for the
		possible, the safety, of non-		Symptom improvement;			treatment of an internal hordeolum. Controlled
C. dala		surgical treatments for acute	Medications;	Symptom resolution;			clinical trials would be useful to determine which
Lindsley	Hordo olum	internal hordeola compared	Other (Lid	Quality of life; Costs;	0	0	interventions are effective for the treatment of
(2017) <sup>49</sup>	Hordeolum	with observation or placebo"	hygiene)	Adverse events	0	U	acute internal hordeola."
		"To investigate the effectiveness and safety of					"Low-certainty evidence suggests that acupuncture with or without conventional treatments may
		acupuncture to treat acute		Symptom resolution;			provide short-termbenefits for treating acute
Cheng		hordeolum compared with no	Medications;	Adverse events; Other			hordeolum when compared with conventional
(2017) <sup>50</sup>	Hordeolum	treatment, sham acupuncture,	Surgeries	outcomes	6	531	treatments alone. The certainty of the evidence
(201/)	Horacolani	a cathlette, shain acupuncture,	Juigeries	outcomes	1	JJ1	treatments alone. The certainty of the evidence

			I		Number	Number of	
Author					of	participants	
(Year) <sup>Ref</sup>	Condition(s)		Type(s) of		included	in included	
(Tear)	• •	Ohiostivas		Outcomes			Conclusion(s) from the chetrost
	addressed	Objectives	interventions	Outcomes	studies	studies	Conclusion(s) from the abstract
		or other active treatment. We					was low to very low mainly due to small sample
		also compared the					sizes, inadequate allocation concealment, lack of
		effectiveness and safety of					masking of the outcome assessors, inadequate or
		acupuncture plus another					unclear randomization method, and a high or
		treatment with that treatment alone."					unreported number of dropouts. All RCTs were
		alone.					conducted in China, which may limit their
							generalizability to non-Chinese populations.  Because no RCTs included a valid sham
							acupuncture control, we cannot rule out a
							potential expectation/placebo effect associated with acupuncture. As resolution is based on clinical
							observation, the outcome could be influenced by
							the observer's knowledge of the assigned
							treatment. Adverse effects of acupuncture were
							reported sparsely in the included RCTs, and, when
							reported, were rare. RCTs with better
							methodology, longer follow-up, and which are
							conducted among other populations are warranted
							to provide more general evidence regarding the
							benefit of acupuncture to treat acute hordeolum."
							"In association with pterygium excision,
							conjunctival autograft is associated with a lower
							risk of recurrence at six months' after surgery than
							amniotic membrane transplant. Participants with
							recurrent pterygia in particular have a lower risk of
		"To assess the safety and					recurrence when they receive conjunctival
		effectiveness of conjunctival					autograft surgery compared with amniotic
		autograft (with or without					membrane transplant. There are few studies
		adjunctive therapy) compared					comparing the two techniques with respect to
		with amniotic membrane graft					visual acuity outcomes, and we identified no
		(with or without adjunctive					studies that reported on vision-related quality of
		therapy) for pterygium. We					life or direct or indirect costs. Comparison of these
		also planned to determine					two procedures in such outcome measures bears
		whether use of MMC yielded					further investigation. There were an insufficient
		better surgical results and to		Visual acuity; Symptom			number of studies that used adjunctive mitomycin
		assess the direct and indirect		improvement; Quality of			C to estimate the effects on pterygium recurrence
Clearfield		comparative costs of these		life; Costs; Other			following conjunctival autograft or amniotic
(2016)51	Pterygium	procedures."	Surgeries	outcomes	20	1866	membrane transplant."
							"Topical or subconjunctival bevacizumab was
		"To assess the efficacy and					relatively safe and well tolerated, but it had no
		safety of bevacizumab in the					statistically significant effect on preventing
		treatment of pterygium and to					pterygium recurrence. A large-scale trial with a
		mainly explore its effects on		Advance average Other			suitable dosage and a longer follow-up would be
11 /204 4\52	Dtomaium	recurrence rate and	Modiacticus	Adverse events; Other		474	required to rule out the possibility of any treatment
Hu (2014) <sup>52</sup>	Pterygium	complications"	Medications	outcomes	9	474	benefit."
Zheng (2012) <sup>53</sup>	Dtomaium	"To compare pterygium	Cummon!	Othor outcom-	12	1776	"According to the current evidence from literature,
(2012)	Pterygium	surgery outcomes using limbal	Surgeries	Other outcomes	13	1776	recurrence rates after pterygium excision with

Author					Number	Number of	
(Year) <sup>Ref</sup>	Co diti o(a)		T a (a) a f		of	participants in included	
(TCar)	Condition(s) addressed	Objectives	Type(s) of interventions	Outcomes	included studies	studies	Conclusion(s) from the abstract
	duiresseu	conjunctival autograft (LCAG) and other techniques"	mervendons	Outcomes	studies	studies	LCAG are lower when compared with the use of bare sclera, bulbar conjunctival autograft, or intraoperative mitomycin C. Although recurrence rates of LCAG were similar to the amniotic membrane graft, further large-scale randomized controlled trials would be required to confirm these results."
Xu (2012) <sup>54</sup>	Pterygium	"To determine the risk for postoperative pterygium recurrence comparing autologous conjunctival transplantation (ACT) versus mitomycin C (MMC)"	Medications; Surgeries	Treatment success; Symptom improvement	8	663	"Conjunctival limbal autograft has better therapy efficacy against the recurrence of pterygium than mitomycin C."
Henein (2017) <sup>55</sup>	Keratoconus	"To compare the visual, refractive and graft outcomes after penetrating keratoplasty (PK) and deep anterior lamellar keratoplasty (DALK) for keratoconus"	Surgeries	Visual acuity; Anatomic outcomes; Other outcomes	18	3367	"We found no evidence to support a difference in outcomes with regards to best-corrected visual acuity (BCVA) at three months post-graft or at any of the other time points analysed."
McAnena (2017) <sup>56</sup>	Keratoconus	"To systematically review the literature to determine the effectiveness of corneal collagen cross-linking (CXL) in children"	Surgeries	Visual acuity; Treatment success; Anatomic outcomes	13	401	"In conclusion it was found that standard CXL may be effective in halting progression of keratoconus in pediatric patients at 1 year. However, larger, more long-term studies are required to ascertain its effectiveness."
Kobashi (2017) <sup>57</sup>	Keratoconus	"To evaluate the efficacy of collagen cross-linking one year after treatment for keratoconus compared to no treatment by summarizing randomized controlled trials using a systematic review"	Surgeries	Visual acuity; Anatomic outcomes; Other outcomes	5	289	"The overall evidence provides a moderate grade level of evidence to support the effectiveness of sublingual immunotherapy for the treatment of allergic rhinitis and asthma, but high-quality studies are still needed to answer questions regarding optimal dosing strategies. There were limitations in the standardization of adverse events reporting, but no life-threatening adverse events were noted in this review."
Alhassan (2014) <sup>58</sup>	Corneal abrasion	"To assess the effectiveness of the various interventions (medical and surgical) for Mooren's ulcer"	Medications; Surgeries	Visual acuity; Quality of life; Costs; Adverse events; Other outcomes	0	0	"We found no evidence in the form of RCTs to assess the treatment effect for the various interventions for Mooren's ulcer. High quality RCTs that compare medical or surgical interventions across different demographics are needed. Such studies should make use of various outcome measures, (i.e. healed versus not healed, percentage of area healed, speed of healing etc.) as well as ensuring high quality. randomisation and data analysis, as highlighted in this review."
Lim (2016) <sup>59</sup>	Corneal abrasion	"To assess the effects of patching for corneal abrasion on healing and pain relief"	Medications; Surgeries	Visual acuity; Symptom resolution; Quality of life; Adverse events;	12	54	"Trials included in this review suggest that treating simple corneal abrasions with a patch may not improve healing or reduce pain."

Author					Number	Number of	
(Year) <sup>Ref</sup>	Condition(s)		Type(s) of		of included	participants in included	
(.ca.,	addressed	Objectives	interventions	Outcomes	studies	studies	Conclusion(s) from the abstract
				Other outcomes			ν,
Watson (2012) <sup>60</sup>	Corneal abrasion	"To assess the effectiveness and safety of prophylactic and treatment regimens for recurrent corneal erosion"	Medications; Devices; Surgeries	Adverse events; Other outcomes	8	441	"Well-designed,masked, randomised controlled trials using standardised methods are needed to establish the benefits of new and existing prophylactic and treatment regimes for recurrent corneal erosion. International consensus is also needed to progress research efforts towards evaluation of the major effective treatments for recurrent corneal erosions."
Wakai (2017) <sup>61</sup>	Corneal injury	"To identify and evaluate all randomised controlled trials (RCTs) comparing the use of topical NSAIDs with placebo or any alternative analgesic interventions in adults with traumatic corneal abrasions (including corneal abrasions arising from foreign body removal), to reduce pain, and its effects on healing time"	Medications; Devices	Other outcomes	9	637	"The findings of the included studies do not provide strong evidence to support the use of topical NSAIDs in traumatic corneal abrasions. This is important, since NSAIDs are associated with a higher cost compared to oral analgesics. None of the trials addressed our primary outcome measure of participant-reported pain intensity reduction of 30% or more or 50% or more at 24 hours."
Abudou (2015) <sup>62</sup>	Patients undergoing corneal transplant	"To assess the effectiveness of immunosuppressants in the prophylaxis of corneal allograft rejection after highand normal-risk kerato-plasty"	Medications	Visual acuity; Treatment success; Quality of life; Costs; Adverse events	6	561	"Current evidence on the effect of immunosuppressants in the prevention of graft failure and rejection after high- and normal-risk keratoplasty is largely low quality because the number of trials was limited, and, in general, the trials were small and at risk of bias."
Akpek (2014) <sup>63</sup>	Patients undergoing corneal transplant	"To assess the effectiveness of artificial versus donor corneas in individuals who have had one or more failed donor corneal transplantations"	Devices	Visual acuity; Treatment success; Quality of life; Costs; Adverse events	0	0	"The optimal management for those individuals who have failed a conventional corneal transplantation is not known."
Bali (2016) <sup>64</sup>	Patients undergoing keratoplasty	"To conduct a systematic review on the efficacy and side effects of systemic immunosuppression for high- risk cornea transplantation"	Medications	Other outcomes	29	Not reported	"Topical or subconjunctival bevacizumab was relatively safe and well tolerated, but it had no statistically significant effect on preventing pterygium recurrence. A large-scale trial with a suitable dosage and a longer follow-up would be required to rule out the possibility of any treatment benefit."
Feng (2013) <sup>65</sup>	Patients undergoing LASIK	"To investigate the possible effect of hinge location on corneal sensation and dry eye syndrome after laser-assisted in situ keratomileusis (LASIK)"	Surgeries	Other outcomes	8	366	"Acute conjunctivitis seen in primary care can be thought of as a self-limiting condition, with most patients getting better regardless of antibiotic therapy. Patients with purulent discharge or a mild severity of red eye may have a small benefit from antibiotics. Prescribing practices need to be updated, taking into account these results."

**eAppendix.** Diseases, Interventions, Outcomes, and Number of Studies and Participants, and Conclusions of all 65 Reliable Systematic Reviews Addressing Corneal Diseases

## **References for this Supplement**

- 1. Papaioannou L, Miligkos M, Papathanassiou M. Corneal Collagen Cross-Linking for Infectious Keratitis: A Systematic Review and Meta-Analysis. *Cornea*. 2016;35(1):62-71.
- 2. Herretes S, Wang X, Reyes JM. Topical corticosteroids as adjunctive therapy for bacterial keratitis. *The Cochrane database of systematic reviews*. 2014(10):Cd005430.
- 3. McDonald EM, Ram FS, Patel DV, McGhee CN. Topical antibiotics for the management of bacterial keratitis: an evidence-based review of high quality randomised controlled trials. *The British journal of ophthalmology*. 2014;98(11):1470-1477.
- 4. O'Gallagher M, Bunce C, Hingorani M, Larkin F, Tuft S, Dahlmann-Noor A. Topical treatments for blepharokeratoconjunctivitis in children. *The Cochrane database of systematic reviews*. 2017;2:Cd011965.
- 5. O'Gallagher M, Banteka M, Bunce C, Larkin F, Tuft S, Dahlmann-Noor A. Systemic treatment for blepharokeratoconjunctivitis in children. *The Cochrane database of systematic reviews*. 2016(5):Cd011750.
- 6. Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis. *The Cochrane database of systematic reviews.* 2012(5):Cd005556.
- 7. van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. *The Cochrane database of systematic reviews*. 2015(4):Cd003262.
- 8. Kam KW, Chen LJ, Wat N, Young AL. Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis. *Ocular immunology and inflammation*. 2017;25(5):663-677.
- 9. Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. *The Cochrane database of systematic reviews*. 2015(6):Cd009566.
- 10. Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. *The Laryngoscope*. 2014;124(3):616-627.
- 11. Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. *Current medical research and opinion*. 2013;29(11):1539-1551.
- 12. Gane J, Buckley R. Leukotriene receptor antagonists in allergic eye disease: a systematic review and meta-analysis. *The journal of allergy and clinical immunology In practice*. 2013;1(1):65-74.
- 13. Wan KH, Chen LJ, Rong SS, Pang CP, Young AL. Topical cyclosporine in the treatment of allergic conjunctivitis: a meta-analysis. *Ophthalmology.* 2013;120(11):2197-2203.

- 14. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. *Jama*. 2013;309(12):1278-1288.
- 15. Lin SY, Erekosima N, Suarez-Cuervo C, et al. AHRQ Comparative Effectiveness Reviews. In: *Allergen-Specific Immunotherapy* for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma: Comparative Effectiveness Review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013.
- 16. Epling J. Bacterial conjunctivitis. *BMJ clinical evidence*. 2012;2012.
- 17. Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U. Antibiotics versus placebo for acute bacterial conjunctivitis. *The Cochrane database of systematic reviews.* 2012(9):Cd001211.
- 18. CADTH. CADTH Rapid Response Reports. In: *Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness.* Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Copyright (c) 2016 Canadian Agency for Drugs and Technologies in Health.; 2016.
- 19. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. *The Cochrane database of systematic reviews.* 2011(7):Cd007685.
- 20. Jefferis J, Perera R, Everitt H, et al. Acute infective conjunctivitis in primary care: who needs antibiotics? An individual patient data meta-analysis. *The British journal of general practice: the journal of the Royal College of General Practitioners*. 2011;61(590):e542-548.
- 21. Roder E, Berger MY, de Groot H, van Wijk RG. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. *Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology.* 2008;19(3):197-207.
- 22. Swamy BN, Chilov M, McClellan K, Petsoglou C. Topical non-steroidal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data. *Ophthalmic epidemiology*. 2007;14(5):311-319.
- 23. Sopo SM, Macchiaiolo M, Zorzi G, Tripodi S. Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature. *Archives of disease in childhood*. 2004;89(7):620-624.
- 24. Owen CG, Shah A, Henshaw K, Smeeth L, Sheikh A. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. *The British journal of general practice : the journal of the Royal College of General Practitioners.* 2004;54(503):451-456.
- 25. Gonzalez-Lopez JJ, Lopez-Alcalde J, Morcillo Laiz R, Fernandez Buenaga R, Rebolleda Fernandez G. Topical cyclosporine for atopic keratoconjunctivitis. *The Cochrane database of systematic reviews*. 2012(9):Cd009078.
- 26. Mantelli F, Santos MS, Petitti T, et al. Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. *The British journal of ophthalmology.* 2007;91(12):1656-1661.
- 27. Chen G, Tzekov R, Li W, Jiang F, Mao S, Tong Y. Deep Anterior Lamellar Keratoplasty Versus Penetrating Keratoplasty: A Meta-Analysis of Randomized Controlled Trials. *Cornea*. 2016;35(2):169-174.
- 28. Sykakis E, Karim R, Evans JR, et al. Corneal collagen cross-linking for treating keratoconus. *The Cochrane database of systematic reviews.* 2015(3):Cd010621.

- 29. Fischer S, Zechmeister-Koss I, Charpentier E. *Intrastromal corneal implants for ectatic corneal disorders. Decision Support Document No. 85.* Vienna, Austria: Ludwig Boltzmann Institute for Health Technology Assessment; 2015.
- 30. Keane M, Coster D, Ziaei M, Williams K. Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus. *The Cochrane database of systematic reviews*. 2014(7):Cd009700.
- 31. Health Quality Ontario. Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis. *Ontario health technology assessment series*. 2009;9(1):1-90.
- 32. Nanavaty MA, Wang X, Shortt AJ. Endothelial keratoplasty versus penetrating keratoplasty for Fuchs endothelial dystrophy. *The Cochrane database of systematic reviews.* 2014(2):Cd008420.
- 33. Calder LA, Balasubramanian S, Fergusson D. Topical nonsteroidal anti-inflammatory drugs for corneal abrasions: metaanalysis of randomized trials. *Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.* 2005;12(5):467-473.
- 34. Flynn CA, D'Amico F, Smith G. Should we patch corneal abrasions? A meta-analysis. *The Journal of family practice*. 1998;47(4):264-270.
- 35. Song JK, Lee K, Park HY, et al. Efficacy of Carboxymethylcellulose and Hyaluronate in Dry Eye Disease: A Systematic Review and Meta-Analysis. *Korean journal of family medicine*. 2017;38(1):2-7.
- 36. Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. *The Cochrane database of systematic reviews*. 2017;2:Cd009327.
- 37. Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. *The Cochrane database of systematic reviews*. 2016;2:Cd009729.
- 38. Wu D, Chen WQ, Li R, Wang Y. Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials. *Cornea*. 2015;34(6):644-650.
- 39. Zhu W, Wu Y, Li G, Wang J, Li X. Efficacy of polyunsaturated fatty acids for dry eye syndrome: a meta-analysis of randomized controlled trials. *Nutrition reviews.* 2014;72(10):662-671.
- 40. Sacchetti M, Mantelli F, Lambiase A, Mastropasqua A, Merlo D, Bonini S. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. *The British journal of ophthalmology.* 2014;98(8):1016-1022.
- 41. Akpek EK, Lindsley KB, Adyanthaya RS, Swamy R, Baer AN, McDonnell PJ. Treatment of Sjogren's syndrome-associated dry eye an evidence-based review. *Ophthalmology*. 2011;118(7):1242-1252.
- 42. Lee MS, Shin BC, Choi TY, Ernst E. Acupuncture for treating dry eye: a systematic review. *Acta ophthalmologica*. 2011;89(2):101-106.
- 43. Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. *The Cochrane database of systematic reviews*. 2010(9):Cd006775.
- 44. Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X. Treatment of primary Sjogren syndrome: a systematic review. *Jama*. 2010;304(4):452-460.

- 45. FlorCruz NV, Evans JR. Medical interventions for fungal keratitis. *The Cochrane database of systematic reviews*. 2015(4):Cd004241.
- 46. Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. *The Cochrane database of systematic reviews.* 2015;1:Cd002898.
- 47. Alkharashi M, Lindsley K, Law HA, Sikder S. Medical interventions for acanthamoeba keratitis. *The Cochrane database of systematic reviews.* 2015(2):Cd010792.
- 48. Barker NH. Ocular herpes simplex. *BMJ clinical evidence*. 2008;2008.
- 49. Lindsley K, Nichols JJ, Dickersin K. Non-surgical interventions for acute internal hordeolum. *The Cochrane database of systematic reviews*. 2017;1:Cd007742.
- 50. Cheng K, Law A, Guo M, Wieland LS, Shen X, Lao L. Acupuncture for acute hordeolum. *The Cochrane database of systematic reviews*. 2017;2:Cd011075.
- 51. Clearfield E, Muthappan V, Wang X, Kuo IC. Conjunctival autograft for pterygium. *The Cochrane database of systematic reviews*. 2016;2:Cd011349.
- 52. Hu Q, Qiao Y, Nie X, Cheng X, Ma Y. Bevacizumab in the treatment of pterygium: a meta-analysis. *Cornea*. 2014;33(2):154-160.
- 53. Zheng K, Cai J, Jhanji V, Chen H. Comparison of pterygium recurrence rates after limbal conjunctival autograft transplantation and other techniques: meta-analysis. *Cornea*. 2012;31(12):1422-1427.
- 54. Xu Y, Zhou HM, Li J, Ke BL, Xu X. Efficacy of treatment for pterygium by autologous conjunctival transplantation and mitomycin C. *Chinese medical journal*. 2012;125(20):3730-3734.
- 55. Henein C, Nanavaty MA. Systematic review comparing penetrating keratoplasty and deep anterior lamellar keratoplasty for management of keratoconus. *Contact lens & anterior eye : the journal of the British Contact Lens Association*. 2017;40(1):3-14.
- 56. McAnena L, Doyle F, O'Keefe M. Cross-linking in children with keratoconus: a systematic review and meta-analysis. *Acta ophthalmologica*. 2017;95(3):229-239.
- 57. Kobashi H, Rong SS. Corneal Collagen Cross-Linking for Keratoconus: Systematic Review. *BioMed research international*. 2017;2017:8145651.
- 58. Alhassan MB, Rabiu M, Agbabiaka IO. Interventions for Mooren's ulcer. *The Cochrane database of systematic reviews*. 2014(1):Cd006131.
- 59. Lim CH, Turner A, Lim BX. Patching for corneal abrasion. *The Cochrane database of systematic reviews.* 2016;7:Cd004764.
- 60. Watson SL, Lee MH, Barker NH. Interventions for recurrent corneal erosions. *The Cochrane database of systematic reviews*. 2012(9):Cd001861.
- 61. Wakai A, Lawrenson JG, Lawrenson AL, et al. Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions. *The Cochrane database of systematic reviews*. 2017;5:Cd009781.

- 62. Abudou M, Wu T, Evans JR, Chen X. Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty. *The Cochrane database of systematic reviews*. 2015(8):Cd007603.
- 63. Akpek EK, Alkharashi M, Hwang FS, Ng SM, Lindsley K. Artificial corneas versus donor corneas for repeat corneal transplants. *The Cochrane database of systematic reviews.* 2014(11):Cd009561.
- 64. Bali S, Filek R, Si F, Hodge W. Systemic Immunosuppression in High-Risk Penetrating Keratoplasty: A Systematic Review. *Journal of clinical medicine research.* 2016;8(4):269-276.
- 65. Feng YF, Yu JG, Wang DD, et al. The effect of hinge location on corneal sensation and dry eye after LASIK: a systematic review and meta-analysis. *Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie.* 2013;251(1):357-366.